Etana And Recce Pharmaceuticals Sign MoU For Clinical Development In Indonesia

Photo: Doc. Etana

JAKARTA - The original Indonesian biofarmation company, PT Etana Biotechnologies Indonesia (Etana) announced the signing of a Memorandum of Understanding (MoU) with Recce Pharmaceuticals Limited ASX:RCE, FSE:R9Q), an Australian company that developed the latest classification of synthetic Anti-Infectives.

The signing of this understanding aims to accelerate the development of clinical anti-ineffective Recess throughout Indonesia, to address critical global health challenges related to antimicrobial resistance (AMR).

This collaboration is a bilateral initiative supported by the Government of Australia and Indonesia. Present at a joint meeting with executives from Recce and Etana, Penny Williams PSM, Australian Ambassador to Indonesia, Indonesian Minister of Health Budi Sadikin, and Head of the National Research and Innovation Agency (BRIN) Laksana Tri Handoko.

In order to strengthen joint efforts to overcome global challenges related to antimicrobial resistance, Nathan Tirtana, President Director of Etana said, Etana and Recce have agreed to cooperate in advancing the Recce clinical program in Indonesia.

"This collaboration will allow the Indonesian government's access to innovative therapies for increasingly urgent infectious diseases," said Nathan, in his statement, Saturday, February 10.

Minister Budi welcomed this collaborative initiative, which emphasized the importance of developing innovative therapies against antimicrobial resistance which is a global issue. Full support has also been provided by the Government of Australia and Indonesia in this historical bilateral initiative.

Global health challenges related to antimicrobial resistance are urgent issues on the world stage. Indonesia welcomes collaborative initiatives and supports efforts to counter antimicrobial resistance, including the development of innovative therapies for infectious diseases, "said Budi.

On the same occasion, the Chairman of BRIN, Laksana, said that health science and biomedicals are important areas in Indonesia's research and innovation. According to him, Indonesia needs to build national capabilities, especially after lessons from the COVID-19 pandemic.

This collaboration is a continuation of the close relationship we have with Australia, which I see will continue to develop in the future. We want to build together expertise and I look forward to work getting started with us," he added.

Meanwhile, Chief Executive Officer of Recce Pharmaceuticals James Graham stated that this collaboration signifies the joint commitment of the Government of Australia and Indonesia to promote public health and overcome the global challenges of AMR in the Asia Pacific region.

"By combining the expertise and resources of the two companies, Etana and Recce believe they can make significant progress in an effort to make a healthier and more resilient future for both countries and the global community," he concluded.

Etana will work with Recce, to advance Recce's clinical program with speed, accessibility, cost effectiveness (including the Government's great support), and quality. By coordinating bilateral efforts between the Government of Australia and Indonesia and industry experts, this will provide Etana with confidence to develop the potential of biopharmaceuticals in Indonesia.